ATE508633T1 - Eprosartan-zusammensetzungen - Google Patents
Eprosartan-zusammensetzungenInfo
- Publication number
- ATE508633T1 ATE508633T1 AT99909780T AT99909780T ATE508633T1 AT E508633 T1 ATE508633 T1 AT E508633T1 AT 99909780 T AT99909780 T AT 99909780T AT 99909780 T AT99909780 T AT 99909780T AT E508633 T1 ATE508633 T1 AT E508633T1
- Authority
- AT
- Austria
- Prior art keywords
- eprosartan
- compositions
- composition
- solvate
- hydrate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002080 C09CA02 - Eprosartan Substances 0.000 title abstract 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 title abstract 2
- 229960004563 eprosartan Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7766098P | 1998-03-11 | 1998-03-11 | |
| PCT/US1999/004651 WO1999045779A1 (en) | 1998-03-11 | 1999-03-11 | Novel compositions of eprosartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE508633T1 true ATE508633T1 (de) | 2011-05-15 |
Family
ID=22139347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99909780T ATE508633T1 (de) | 1998-03-11 | 1999-03-11 | Eprosartan-zusammensetzungen |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1061803B1 (de) |
| JP (1) | JP2002506010A (de) |
| KR (1) | KR20010041796A (de) |
| CN (1) | CN1299235A (de) |
| AT (1) | ATE508633T1 (de) |
| AU (1) | AU757547B2 (de) |
| BR (1) | BR9908691A (de) |
| CA (1) | CA2323363C (de) |
| CY (1) | CY1111738T1 (de) |
| CZ (1) | CZ303067B6 (de) |
| DK (1) | DK1061803T3 (de) |
| ES (1) | ES2366394T3 (de) |
| HU (1) | HU228574B1 (de) |
| IL (1) | IL138345A (de) |
| NO (1) | NO331207B1 (de) |
| NZ (1) | NZ506700A (de) |
| PL (1) | PL192545B1 (de) |
| SI (1) | SI1061803T1 (de) |
| TR (1) | TR200002646T2 (de) |
| WO (1) | WO1999045779A1 (de) |
| ZA (1) | ZA991922B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4484247B2 (ja) | 1995-02-24 | 2010-06-16 | エラン ファーマ インターナショナル，リミティド | ナノ粒子分散体を含有するエアロゾル |
| NZ509378A (en) * | 1998-07-20 | 2003-04-29 | Smithkline Beecham Corp | Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| HUP0301335A3 (en) * | 2000-04-12 | 2006-02-28 | Novartis Ag | Combination of organic compounds |
| DE10230272A1 (de) * | 2002-07-05 | 2004-01-22 | Solvay Pharmaceuticals Gmbh | AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen |
| EP1382334A1 (de) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Verwendung von Angiotensin II AT1-Rezeptorblockern, allein oder in Kombination mit Thiazide oder Angiotensin II zur Behandlung von Schlaganfall |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| WO2004064834A1 (en) * | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
| KR20120058618A (ko) | 2003-01-31 | 2012-06-07 | 다이이찌 산쿄 가부시키가이샤 | 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약 |
| CN1972679B (zh) * | 2004-06-23 | 2010-07-28 | 索尔瓦药物有限公司 | 包括nep-抑制剂、内源性内皮缩血管肽产生系统抑制剂和at1受体拮抗剂的药物组合物 |
| US20060099230A1 (en) * | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
| WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
| KR100715355B1 (ko) * | 2005-09-30 | 2007-05-07 | 주식회사유한양행 | 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법 |
| WO2009013760A2 (en) * | 2007-07-25 | 2009-01-29 | Hetero Drugs Limited | Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan |
| EP2108365A1 (de) * | 2008-04-09 | 2009-10-14 | LEK Pharmaceuticals d.d. | Pharmazeutische Einzeldosisformulierung mit Eprosartan-Mesylat |
| CN103705510A (zh) * | 2013-12-27 | 2014-04-09 | 华润赛科药业有限责任公司 | 一种阿齐沙坦固体组合物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| JPS587609B2 (ja) | 1979-06-17 | 1983-02-10 | フロイント産業株式会社 | 粉体薬剤のコ−テング法 |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| JP2642486B2 (ja) | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| BR9708336A (pt) * | 1996-03-29 | 1999-08-03 | Smithkline Beecham Corp | Diidrato de eprosartan e processo para sua produção e formulação |
| DK1027047T3 (da) * | 1997-08-06 | 2007-01-29 | Smithkline Beecham Corp | Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering |
-
1999
- 1999-03-10 ZA ZA9901922A patent/ZA991922B/xx unknown
- 1999-03-11 CA CA002323363A patent/CA2323363C/en not_active Expired - Fee Related
- 1999-03-11 PL PL343411A patent/PL192545B1/pl not_active IP Right Cessation
- 1999-03-11 AU AU28909/99A patent/AU757547B2/en not_active Ceased
- 1999-03-11 BR BR9908691-3A patent/BR9908691A/pt not_active Application Discontinuation
- 1999-03-11 TR TR2000/02646T patent/TR200002646T2/xx unknown
- 1999-03-11 KR KR1020007010070A patent/KR20010041796A/ko not_active Ceased
- 1999-03-11 CN CN99805844A patent/CN1299235A/zh active Pending
- 1999-03-11 EP EP99909780A patent/EP1061803B1/de not_active Expired - Lifetime
- 1999-03-11 NZ NZ506700A patent/NZ506700A/xx not_active IP Right Cessation
- 1999-03-11 IL IL13834599A patent/IL138345A/en not_active IP Right Cessation
- 1999-03-11 JP JP2000535205A patent/JP2002506010A/ja not_active Ceased
- 1999-03-11 WO PCT/US1999/004651 patent/WO1999045779A1/en not_active Ceased
- 1999-03-11 CZ CZ20003288A patent/CZ303067B6/cs not_active IP Right Cessation
- 1999-03-11 HU HU0101243A patent/HU228574B1/hu not_active IP Right Cessation
- 1999-03-11 AT AT99909780T patent/ATE508633T1/de active
- 1999-03-11 DK DK99909780.1T patent/DK1061803T3/da active
- 1999-03-11 ES ES99909780T patent/ES2366394T3/es not_active Expired - Lifetime
- 1999-03-11 SI SI9931058T patent/SI1061803T1/sl unknown
-
2000
- 2000-09-08 NO NO20004502A patent/NO331207B1/no not_active IP Right Cessation
-
2011
- 2011-07-25 CY CY20111100730T patent/CY1111738T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200002646T2 (tr) | 2001-01-22 |
| HUP0101243A1 (hu) | 2002-05-29 |
| EP1061803A1 (de) | 2000-12-27 |
| IL138345A (en) | 2004-12-15 |
| CZ20003288A3 (cs) | 2001-03-14 |
| CA2323363C (en) | 2008-09-30 |
| CA2323363A1 (en) | 1999-09-16 |
| PL192545B1 (pl) | 2006-11-30 |
| AU2890999A (en) | 1999-09-27 |
| NZ506700A (en) | 2003-03-28 |
| NO20004502D0 (no) | 2000-09-08 |
| EP1061803B1 (de) | 2011-05-11 |
| NO20004502L (no) | 2000-11-07 |
| EP1061803A4 (de) | 2007-12-26 |
| CY1111738T1 (el) | 2015-10-07 |
| CN1299235A (zh) | 2001-06-13 |
| DK1061803T3 (da) | 2011-08-29 |
| NO331207B1 (no) | 2011-10-31 |
| HUP0101243A3 (en) | 2005-09-28 |
| ZA991922B (en) | 1999-09-13 |
| BR9908691A (pt) | 2000-12-26 |
| JP2002506010A (ja) | 2002-02-26 |
| ES2366394T3 (es) | 2011-10-19 |
| KR20010041796A (ko) | 2001-05-25 |
| IL138345A0 (en) | 2001-10-31 |
| WO1999045779A1 (en) | 1999-09-16 |
| PL343411A1 (en) | 2001-08-13 |
| SI1061803T1 (sl) | 2011-09-30 |
| CZ303067B6 (cs) | 2012-03-21 |
| AU757547B2 (en) | 2003-02-27 |
| HU228574B1 (en) | 2013-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111738T1 (el) | Συνθeσεις επροσαρτανης | |
| WO2000004862A3 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
| MY127793A (en) | Novel form of s-omeprazole. | |
| RO118870B1 (ro) | Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice | |
| AU7743001A (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
| DE69928655D1 (de) | Substituierte porphyrine | |
| JO2481B1 (en) | Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods | |
| ATE219074T1 (de) | Neue salzform von pantoprazol | |
| PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
| MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. | |
| MXPA05005198A (es) | Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina. | |
| NO20031033L (no) | Reseptor i EDb-fibronectindomene | |
| WO2006052461A3 (en) | Novel formulations of eprosartan with enhanced bioavailability | |
| MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
| DE60129933D1 (de) | Verfahren zum screening | |
| DE602004031355D1 (de) | Neue 1,3-disubstituierte azetidinderivate zur verwendung als liganden des 5ht2a-rezeptors | |
| FR2842516B1 (fr) | Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1061803 Country of ref document: EP |